Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ŒUrothelial Carcinoma Reached its Pr

7 hours ago 1

1. Homepage
2. Finance
3. Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ŒUrothelial Carcinoma Reached its Pr